The stock closed at 1,322.95 rupees on Thursday as the BSE Sensex fell 0.75% to 76,913.50 in a broadly weak Indian market session.
Dr. Reddy's ended 3.99% below its 52-week high of 1,377.95 rupees, reached on 12 June.
Among peers, Lupin slipped 0.27% and Zydus Lifesciences dropped 2.08%, while Wockhardt rose 0.28%; trading volume was 62,413, below the 50-day average of 87,799.
Dr. Reddy's stock beat the market but got downgraded by analysts. Is this pharma giant a safe haven or a hidden risk?
After a key drug approval in Canada but rejection in Brazil, can Dr. Reddy's win the billion-dollar global weight-loss drug race?